SynthesisFrontiers in pharmacology2025

Re-evaluation of the efficacy and safety of anti-Aβ monoclonal antibodies (lecanemab/donanemab) in the treatment of early Alzheimer's disease.

Haoyang Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.